IDEXX Laboratories Financial Ratios
NASDAQ: IDXXHealthcareDiagnostics & ResearchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories ratio analysis
IDEXX Laboratories earned a net margin of 24.6% in FY 2025, up from 22.8% a year earlier. Gross margin was 61.8% compared with a median of 58.0% over the prior 9 years. Return on equity reached 66.0%, meaning IDEXX Laboratories generated 0.66 dollars of profit for every dollar of shareholders' equity, an unusually high figure that often reflects a small equity base after share buybacks.
Debt-to-equity stood at 0.28 versus 0.39 the year before, and the current ratio was 1.23. At the end of FY 2025, IDXX traded at 51.2 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 38.9 to 76.6, with a median of 52.2. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 51.22 | 38.94 | 55.17 | 50.80 | 76.57 | 74.50 | 54.15 | 44.00 | 53.19 | 48.06 |
| Price / sales | 12.52 | 8.79 | 12.59 | 10.13 | 17.45 | 15.76 | 9.47 | 7.36 | 6.97 | 5.93 |
| Price / book | 33.57 | 21.48 | 31.06 | 56.04 | 81.31 | 67.49 | 128.47 | — | — | — |
| Gross margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% |
| Operating margin | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% |
| Net margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
| Free cash flow margin | 24.6% | 20.7% | 21.1% | 11.7% | 19.8% | 20.0% | 12.6% | 12.8% | 15.2% | 15.4% |
| Return on equity (ROE) | 66.0% | 55.7% | 56.9% | 111.6% | 107.9% | 92.0% | 241.0% | — | — | — |
| Return on assets (ROA) | 31.6% | 27.0% | 25.9% | 24.7% | 30.6% | 25.4% | 23.3% | 24.5% | 15.4% | 14.5% |
| Debt / equity | 0.28 | 0.39 | 0.47 | 1.26 | 1.23 | 1.44 | 3.94 | — | — | — |
| Current ratio | 1.23 | 1.31 | 1.57 | 0.89 | 1.25 | 1.82 | 0.94 | 0.85 | 0.97 | 0.90 |
| Revenue growth | 10.4% | 6.5% | 8.7% | 4.7% | 18.8% | 12.5% | 8.8% | 12.4% | 10.9% | 10.8% |
| EPS growth | 22.6% | 6.1% | 25.3% | -6.6% | 28.2% | 37.2% | 14.8% | 44.9% | 20.5% | 19.0% |